With the help of prescription medications and a whole lot of moisturizing, it’s possible to keep dermatitis under control.

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...

Rezpegaldesleukin is currently being investigated in the phase 2b REZOLVE-AD study (ClinicalTrials.gov Identifier: NCT06136741) in 398 adult patients with moderate to severe atopic dermatitis who ...

US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...

Experiencing stressful life events in childhood was associated with an increased risk for active and severe atopic dermatitis ...

Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...

Northwestern University researchers have tested a method to reduce the dreaded nocturnal itch-scratch cycle. Using an ...